

Sarvari V Yellapragada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3957912/publications.pdf>

Version: 2024-02-01

18
papers

135
citations

1307594

7
h-index

1281871

11
g-index

18
all docs

18
docs citations

18
times ranked

245
citing authors

#	ARTICLE	IF	CITATIONS
1	The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 843.	3.7	12
2	Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1084-1093.	6.3	10
3	Second primary malignancies (SPM) in African American (AA) and white patients with multiple myeloma in the National Veterans Affairs (VA) healthcare system.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10507-10507.	1.6	2
4	Contemporary Analysis of Electronic Frailty Measurement in Older Adults with Multiple Myeloma Treated in the National US Veterans Affairs Healthcare System. <i>Cancers</i> , 2021, 13, 3053.	3.7	15
5	The detrimental association between fear of falling and motor performance in older cancer patients with chemotherapy-induced peripheral neuropathy. <i>Gait and Posture</i> , 2021, 88, 161-166.	1.4	8
6	Treatment Options for Relapsed and Refractory Multiple Myeloma. <i>JAMA Oncology</i> , 2021, 7, 1449-1450.	7.1	1
7	Using wearables to screen motor performance deterioration because of cancer and chemotherapy-induced peripheral neuropathy (CIPN) in adults - Toward an early diagnosis of CIPN. <i>Journal of Geriatric Oncology</i> , 2019, 10, 960-967.	1.0	33
8	Multimorbidity patterns and their association with survival in a large national cohort of older veterans with multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8033-8033.	1.6	3
9	HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e143-e146.	0.4	15
10	Lack of racial disparity in outcome of African American (AA) and Caucasian patients with symptomatic multiple myeloma (MM) at the Veterans Affairs (VA) hospitals.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8033-8033.	1.6	1
11	Significant improvement in overall survival among patients diagnosed with low-risk myelodysplastic syndrome treated with selective serotonin reuptake inhibitors. <i>British Journal of Haematology</i> , 2017, 177, 142-144.	2.5	3
12	Differential response to carfilzomib based on initial therapy with bortezomib in multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e19515-e19515.	1.6	2
13	State-of-the-Art Imaging and Staging of Plasma Cell Dyscrasias. <i>Radiologic Clinics of North America</i> , 2016, 54, 581-596.	1.8	11
14	Pulmonary Complications of Azanucleoside Therapy in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia. <i>Case Reports in Hematology</i> , 2015, 2015, 1-5.	0.4	5
15	Progressive transfusion and growth factor independence with adjuvant sertraline in low risk myelodysplastic syndrome treated with an erythropoiesis stimulating agent and granulocyte-colony stimulating factor. <i>Leukemia Research Reports</i> , 2015, 4, 1-3.	0.4	10
16	Evaluating the Efficacy and Toxicity of Two Lenalidomide Dose Regimens for the Treatment of Older Relapsed Multiple Myeloma Patients with Co-Morbidities: A Multi-Site Study at the Veteran's Administration Hospitals. <i>Blood</i> , 2015, 126, 5370-5370.	1.4	1
17	Survival outcome of veterans with myelodysplastic syndrome (MDS) treated with statins.. <i>Journal of Clinical Oncology</i> , 2012, 30, e17018-e17018.	1.6	3
18	A Monoclonal Antibody to Lactadherin Inhibits Sickle Red Blood Cell Adhesion to Vascular Endothelial Cells in a Plasma Milieu.. <i>Blood</i> , 2006, 108, 1236-1236.	1.4	0